Sign up
Pharma Capital
Market: AIM
52-week High/Low: 0.93p / 0.45p
Sector: Pharma & Biotech
Market Cap: 16.82M

Sareum discovers and develops innovative drug candidates aimed at cancers and autoimmune diseases. Our drug development programmes aim to improve outcomes for patients with serious medical conditions and where current therapies are inadequate.

Sareum Holdings PLC

Interactive graph

col 3
col 4
col 5
col 6

Big picture - Why invest in Sareum Holdings PLC

Broker Hybridan reckons Sareum is “arguably a bargain target for the relatively large group of biotech and pharma companies interested in TYK2 and the wider JAK inhibitor space”

Sareum Holdings PLC Snapshot


Our strategy

Sareum’s strategy is to develop programmes to late preclinical or early clinical stages to take advantage of the higher asset values associated with licensing programmes at these stages.



Pursue multiple programmes
  • Increase potential success rate
  • Mitigate development risk
Seek collaboration partners
  • Spread financial cost and risk
  • Introduce specialist research expertise

Develop programmes to pre-clinical/
early clinical development

  • Minimise ongoing development risk
  • Move up value chain
  • Potential for higher deal values




Sareum's pipeline is built on the drug discovery expertise of its founders, particularly in the field of cancer.

Sareum operates a collaborative and outsourced business model. All our laboratory-based research is carried out in the laboratories of collaborators or third-party providers. This enables us to access drug discovery expertise throughout the world with a very flexible cost base.

Discovery Programmes Jun15

Click here for our latest research update

Drug Discovery

Discovery Platform

Autoimmune - TYK2 Kinase

Cancer - TYK2 Kinase

Other Programmes




Stephen Parker DPhil, MBA - Non-executive Chairman

Dr Stephen Parker, aged 59, has a career in the healthcare and pharma sector that spans over 30 years, including six years in the City in advisory roles. He has sector corporate finance experience having been an investment banker focusing on pharma and biotechnology with Barings, Warburg and Apax Partners and has previously held roles as a partner at Celtic Pharma and Chief Financial Officer of Oxford GlycoSciences. Stephen is also a Non-executive Director at Silence Therapeutics plc.

Tim Mitchell PhD - Founder and CEO

Dr Tim Mitchell, aged 57, has a wide breadth of management, business and research expertise gained over 30 years in the biotech, large pharmaceutical and research service companies.

He is the inventor of Oblean® (cetilistat) for which Takeda have obtained sales approval in the Japanese market for the treatment of obesity with complications.

Prior to co-founding Sareum he was Director of Structure-Based Discovery at Millennium Pharmaceuticals, Director of Computational Chemistry at Cambridge Discovery Chemistry, and Team Leader at SmithKline Beecham Pharmaceuticals. Tim has a PhD in Computational Chemistry and a BSc in Chemistry.

John Reader PhD - Founder and CSO

Dr John Reader, aged 51, has 25 years' experience within the industry. His previous roles include Associate Director, Chemical Technologies at Millennium Pharmaceuticals Research and Development Ltd, Pharmacopeia Inc., and Cambridge Discovery Chemistry.

John has an excellent track record of delivering successful drug research projects. He has authored or co-authored many publications and patents on small molecule drug discovery. John is a member of the EPSRC Peer Review College and has a PhD in Chemistry and a BSc in Applied Chemistry.

Scientific Advisory Board

Harry Finch PhD

Dr Finch has many years’ experience in the Pharmaceutical industry and is currently Executive Vice President at Pulmagen Therapeutics. He was previously Executive VP of Argenta Discovery, a Director at RiboTargets and spent 24 years at GlaxoSmithKline and its predecessor companies, latterly as Director of Chemistry for UK Research & Development.

Harry has extensive experience in a wide range of therapeutic areas. He was a co-inventor of Salmeterol (Serevent; GSK), a successful long-acting bronchodilator for asthma and has 45 patents and 49 publications to his name.

Bob Jackson PhD

Dr Jackson was formerly Chief Scientific Officer at the cancer drug discovery company, Cyclacel Limited. Prior to that, he held senior research positions at Celltech, Agouron, DuPont and Warner-Lambert. Dr Jackson has led teams that have developed 26 compounds to clinical trials, including the Aurora Kinase inhibitor CYC116, and gained his PhD in biochemistry from the University of London.

Head office

Sareum Limited.
Unit 2A, Langford Arch
London Road, Pampisford
CB22 3FX
United Kingdom

tel: +44 (0) 1223 497700
fax: +44 (0) 1223 497701

Hybridan LLP
20 Ironmonger Lane


Capita Asset Services
The Registry
34 Beckenham Rd
Kent  BR3 4TU


Shipleys LLP
10 Orange Street


Nominated Adviser
WH Ireland Limited
24 Martin Lane


Taylor Vinters
Merlin Place
Milton Road


Financial PR
Citigate Dewe Rogerson
3 London Wall Buildings
London EC2M 5SY

View full SAR profile View Profile

Sareum Holdings primed for progress

View All

Columns Including SAR


Market Reports Including SAR


Executive video interviews


© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.